{
    "answer": "EC approved Kisqali as an adjuvant treatment in combination with an aromatase inhibitor for patients with HR+/HER2- early breast cancer at high risk of recurrence.",
    "ground_truth": "Treating hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (adjuvant)",
    "rewards": [
        0,
        0,
        1
    ],
    "reward_sum": 1,
    "turns": 3,
    "search count": 2,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        812,
        2218,
        3537
    ]
}